The development of monoclonal antibodies that recognize tumor-associated antigens has led to significantly greater practical possibilities for producing highly specific radiolabeled antibodies for diagnosis and therapy of human tumors. A number of problems remain before this technique will be ready for routine clinical application however. Achieving the high target to background ratio that are predicted on theoretical grounds is a major challenge in cancer investigation.
No takes yet. Share an insight, caveat, or question.
Larson et al. (1984) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: